Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Middeke, JM; Teipel, R; Röllig, C; Stasik, S; Zebisch, A; Sill, H; Kramer, M; Scholl, S; Hochhaus, A; Jost, E; Brümmendorf, TH; Naumann, R; Steffen, B; Serve, H; Altmann, H; Kunzmann, V; Einsele, H; Parmentier, S; Schaich, M; Burchert, A; Neubauer, A; Schliemann, C; Berdel, WE; Sockel, K; Stölzel, F; Platzbecker, U; Ehninger, G; Bornhäuser, M; Schetelig, J; Thiede, C, , Study, Alliance, Leukemia, (SAL).
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.
Leuk Lymphoma. 2021; 62(6):1432-1440
Doi: 10.1080/10428194.2020.1864354
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Sill Heinz
- Zebisch Armin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We performed a registry-based analysis of 311 AML patients treated with decitabine in a standard of care setting to assess response and survival data with a distinct focus on the impact of the TP53 mutation status. Median age was 73 years. 172 patients received decitabine first-line and 139 in r/r disease. The ORR (whole cohort) was 30% with a median overall survival of 4.7 months. First-line patients achieved better responses than r/r-patients (ORR: 38% vs. 21%) resulting in a median OS of 5.8 months vs. 3.9 months. NGS based mutation analysis was performed in 180 patients. 20 patients (11%) harbored a TP53 mutation. Response rates and survival did not differ significantly between TP53 mutated patients and wild-type patients. This analysis of a large cohort of AML patients provides response rates and OS data after decitabine treatment. Interestingly, outcome was not negatively influenced by a TP53 mutation.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- DNA Mutational Analysis - administration & dosage
- Decitabine - therapeutic use
- Humans - administration & dosage
- Leukemia, Myeloid, Acute - diagnosis, drug therapy, genetics
- Mutation - administration & dosage
- Registries - administration & dosage
- Treatment Outcome - administration & dosage
- Tumor Suppressor Protein p53 - genetics
- Find related publications in this database (Keywords)
- AML
- decitabine
- TP53mutation